Navigenics Founder Blasts Myriad's BRACAnalysis Pricing

David Agus calls for legislative action to prevent monopolies, such as Myriad's around BRCA 1 and BRCA 2 genes, that have life and death implications.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

If patents are legislatively

If patents are legislatively nullified ad hoc and ad libiditum the whole concept becomes worthless. I do like the idea, however of criteria triggering strong encouragement for companies to license to an insurance consortium wholesale, after which they then have to compete with other providers for the business. I hope something like this develops.

Whatever happened to

Whatever happened to Helicos's BRAC 1/2 tests that had the ability to potentially circumvent Myriad's monopolistic position ? What a sordid sordid story indeed